Co-Authors
This is a "connection" page, showing publications co-authored by Bikash Medhi and Anusuya Bhattacharyya.
Connection Strength
6.676
-
Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jul-Aug; 53(4):317-327.
Score: 0.954
-
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Ann Intern Med. 2021 03; 174(3):434.
Score: 0.932
-
Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2020 Jul-Aug; 52(4):313-323.
Score: 0.890
-
Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. Indian J Pharmacol. 2021 Jul-Aug; 53(4):310-316.
Score: 0.238
-
nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis. Sci Rep. 2021 06 18; 11(1):12888.
Score: 0.238
-
Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review. Phytother Res. 2021 Aug; 35(8):4456-4484.
Score: 0.238
-
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Eur J Pharmacol. 2021 Sep 05; 906:174233.
Score: 0.237
-
Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD. Comput Biol Med. 2021 07; 134:104495.
Score: 0.236
-
Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings. J Biomol Struct Dyn. 2021 May 13; 1-11.
Score: 0.236
-
Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable? Med Hypotheses. 2021 Apr; 149:110539.
Score: 0.233
-
Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. Tissue Cell. 2021 Jun; 70:101497.
Score: 0.232
-
Indian contribution toward biomedical research and development in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jan-Feb; 53(1):63-72.
Score: 0.230
-
Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis. Indian J Pharmacol. 2020 Nov-Dec; 52(6):535-550.
Score: 0.228
-
Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020 Sep-Oct; 52(5):414-421.
Score: 0.225
-
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. J Mol Graph Model. 2020 12; 101:107716.
Score: 0.225
-
Letter to the editor: Possible role of topical povidone iodine in case of accidental ocular exposure to SARS-CoV-2. Graefes Arch Clin Exp Ophthalmol. 2020 11; 258(11):2575-2578.
Score: 0.224
-
Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol. 2020 Mar-Apr; 52(2):142-149.
Score: 0.221
-
Possible prophylactic or preventive role of topical povidone iodine during accidental ocular exposure to 2019-nCoV. Graefes Arch Clin Exp Ophthalmol. 2020 11; 258(11):2563-2565.
Score: 0.221
-
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020 07; 92(7):776-785.
Score: 0.220
-
Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020 Jan-Feb; 52(1):56-65.
Score: 0.218